Top

Pediatric Nephrology

Published in:

01-07-2017 | Letter to the Editors

Conversion from immediate- to extended-release cysteamine may decrease disease control and increase additional side effects

Authors: Sören Bäumner, Lutz T. Weber

Published in: Pediatric Nephrology | Issue 7/2017

Excerpt

Dear Editors, …

Ahlenstiel-Grunow T, Kanzelmeyer NK, Froede K, Kreuzer M, Drube Lerch C, Pape L (2017) Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study. Pediatr Nephrol 32:91–97CrossRefPubMed

Title: Conversion from immediate- to extended-release cysteamine may decrease disease control and increase additional side effects
Authors: Sören Bäumner
Lutz T. Weber
Publication date: 01-07-2017
Publisher: Springer Berlin Heidelberg
Published in: Pediatric Nephrology / Issue 7/2017
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-017-3618-3

At a glance: The STEP trials

Springer Medicine

Conversion from immediate- to extended-release cysteamine may decrease disease control and increase additional side effects

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 7/2017

Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients

Delayed graft function and its management in children

Clinical outcomes in children with Henoch–Schönlein purpura nephritis without crescents

Congenital eyelid ptosis, decreased glomerular filtration, and orthostatic hypotension: Answers

Membrane pressures predict clotting of pediatric continuous renal replacement therapy circuits

Potassium: friend or foe?